Faslodex (Fulvestrant Vials) 250mg

Faslodex (fulvestrant) 250mg vials are prescribed for hormone receptor-positive breast cancer in postmenopausal women. This injectable estrogen receptor antagonist supports advanced cancer treatment plans. Store between 2-8°C to maintain potency. Always follow healthcare provider guidance when using.

Strength

250mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Astrazeneca

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Faslodex 250mg vials are used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. It works by blocking estrogen receptors, slowing cancer cell growth. This medication is often prescribed after other hormonal therapies. It may also be used in combination with other treatments for advanced cases.

Side Effects

Faslodex may cause mild injection site reactions like pain or redness. Some users report hot flashes, nausea, or fatigue as common effects. Headaches and bone pain are occasionally noted. These effects vary by individual and typically lessen over time. Always report persistent discomfort to a healthcare provider.

Precautions & Warnings

Keep Faslodex vials refrigerated between 2-8°C and protect from light. Avoid freezing or shaking the vials. Use within the recommended timeframe after opening. Inform your doctor about any allergies or bleeding disorders before use. Regular monitoring may be required during treatment.

Avoid Interactions

Faslodex may interact with blood thinners like warfarin or hormonal therapies. Avoid alcohol and grapefruit products as they can affect metabolism. Certain medications, including CYP3A4 inhibitors, may alter fulvestrant levels. Always disclose all medications to your healthcare provider before starting Faslodex.

References

Frequently Asked Questions

Faslodex is used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women.

Faslodex is given as an intramuscular injection, typically in a healthcare setting.

Common side effects include injection site pain, hot flashes, nausea, and fatigue.

No, Faslodex must be refrigerated between 2-8°C and protected from light.

Yes, Faslodex may interact with blood thinners, hormonal therapies, and CYP3A4 inhibitors.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.